Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Hematol ; 103(6): 1931-1940, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38478023

ABSTRACT

Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9% to 26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.


Subject(s)
Medication Adherence , Nitriles , Polycythemia Vera , Primary Myelofibrosis , Pyrazoles , Pyrimidines , Humans , Primary Myelofibrosis/drug therapy , Pyrimidines/therapeutic use , Pyrazoles/therapeutic use , Male , Polycythemia Vera/drug therapy , Female , Prospective Studies , Aged , Middle Aged , Italy/epidemiology , Medication Adherence/statistics & numerical data , Aged, 80 and over , Adult
4.
Eur Rev Med Pharmacol Sci ; 26(23): 8984-8989, 2022 12.
Article in English | MEDLINE | ID: mdl-36524517

ABSTRACT

OBJECTIVE: Due to the high mortality rate of COVID-19, the assessment of BNT162b2 SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech) efficacy in allogeneic hematopoietic stem cell transplant (HSCT) recipients is mandatory. PATIENTS AND METHODS: We conducted a single-center pilot study with the main objective of evaluating the immunogenicity of the BNT162b2 mRNA vaccine in 31 hematological patients who underwent hematopoietic stem cell transplantation within the previous 12 months and/or were affected by chronic graft-vs.-host-disease (cGVHD), by the assessment of antibody levels at 30-45 days after the second dose of vaccine. RESULTS: After the second dose of vaccine, 23 out of 31 patients (74%) showed a positive immune response. The presence of severe cGVHD or Ig deficiency identified 7 out of 8 (85%) of non-responders. The median absolute cluster of differentiation 19 (CD19) count was significantly lower in non-responders vs. responders (109/µl vs. 351/µl). Underlying pathology, comorbidities, type of donor, time intervals from transplant and cluster of differentiation 3/cluster of differentiation 4/cluster of differentiation 8 (CD3/CD4/CD8) subsets were not significantly associated with an effective immune response to vaccination. CONCLUSIONS: Despite the limited sample of patients enrolled, our findings suggest that hypogammaglobulinemia and cGVHD could be associated with poor humoral response to the BNT162b2.


Subject(s)
Agammaglobulinemia , Bronchiolitis Obliterans Syndrome , COVID-19 , Hematopoietic Stem Cell Transplantation , Humans , BNT162 Vaccine , COVID-19 Vaccines , RNA, Messenger , Pilot Projects , COVID-19/prevention & control , SARS-CoV-2
5.
J Endocrinol Invest ; 45(2): 291-300, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34283388

ABSTRACT

PURPOSE: Thyroid alterations including de novo appearance of thyroid autoimmunity are adverse effects of tyrosine kinase inhibitors, used in solid and hematologic cancer therapy, but the relationship between thyroid alterations during this treatment and the outcome of chronic myeloid leukemia remains unclear. Aim of this study was to investigate whether the presence of thyroid alterations may affect the clinical outcome of chronic myeloid leukemia on tyrosine kinase inhibitors. METHODS: We evaluated thyroid function and autoimmunity in 69 chronic myeloid leukemia patients on long-term therapy looking at the association between thyroid abnormalities and disease molecular response. RESULTS: Overall, 24 of 69 (34.8%) had one or more thyroid abnormalities during therapy. A high percentage of patients (21/69, 30.4%) showed thyroid autoimmunity (positive thyroid autoantibodies with ultrasound hypoechogenicity), while clinical and subclinical hypothyroidism and subclinical hyperthyroidism were, respectively, found in 4 of 69 (5.8%) and 3 of 69 (4.3%) of cases. Second-generation tyrosine kinase inhibitors resulted significantly associated (14/32, 43.7%) with Hashimoto's thyroiditis, compared to first generation (7/37, 18.9%; p = 0.03). Interestingly, we also found a significant association between euthyroid (14/26, 53.8%) and hypothyroid Hashimoto's thyroiditis (4/26, 15.4%) in patients with deep molecular response, as compared to euthyroid (3/43, 7%; p = 0.0001) and hypothyroid (0/43, 0%; p = 0.02) Hashimoto's thyroiditis patients with major molecular response. CONCLUSIONS: Our study confirms and extends our knowledge on the tyrosine kinase inhibitors effects on thyroid, showing that thyroid autoimmunity is frequently observed in chronic myeloid leukemia patients on long-term therapy and is associated with a better oncological response.


Subject(s)
Hypothyroidism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors , Thyroid Gland , Thyroiditis, Autoimmune , Autoantibodies/blood , Drug Monitoring/methods , Drug Monitoring/statistics & numerical data , Female , Humans , Hypothyroidism/etiology , Hypothyroidism/immunology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Long Term Adverse Effects/etiology , Long Term Adverse Effects/immunology , Male , Middle Aged , Prognosis , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Thyroid Function Tests/methods , Thyroid Gland/diagnostic imaging , Thyroid Gland/drug effects , Thyroid Gland/immunology , Thyroiditis, Autoimmune/blood , Thyroiditis, Autoimmune/chemically induced , Thyroiditis, Autoimmune/diagnosis , Treatment Outcome , Ultrasonography/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...